vTv Therapeutics

Company snapshot

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its d

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 50 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for vTv Therapeutics. Not investment advice.

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 60

• Peer + 0 momentum

  Hospital Authority

  TA overlap score 40

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

• Peer + 0 momentum

  Sanofi Pasteur MSD

  TA overlap score 36.6

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Cognition Therapeutics

  TA overlap score 26.6

• Peer + 0 momentum

  SANGAMO THERAPEUTICS

  TA overlap score 25

• Peer + 0 momentum

  Hong Kong Baptist

  TA overlap score 23.6

• Peer + 0 momentum

  Oramed Pharmaceuticals

  TA overlap score 22.8

• Peer + 0 momentum

  Dong Wang

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for vTv Therapeutics.

1. Jun 8, 2026 Clinical update

   TTP889 — Phase 2

2. Jun 5, 2026 Clinical update

   TTP4000 — Phase 1

3. Jun 5, 2026 Clinical update

   Azeliragon — Phase 3

4. Jun 5, 2026 Clinical update

   Azeliragon — Phase 2

5. Jun 5, 2026 Clinical update

   Azeliragon 5mg — Phase 3

View all clinical trial activity →

• What is vTv Therapeutics?

  vTv Therapeutics is a pharma organization headquartered in High Point, USA. It trades on NYSE under ticker VTVT. Primary therapeutic focus areas include Alzheimer's Disease, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1, Coagulation, Alzheimer Disease. NovaPharmaNews links

• Is vTv Therapeutics publicly traded?

  Yes. vTv Therapeutics is listed with ticker VTVT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does vTv Therapeutics develop or market?

  We link 2 drug profile(s) where vTv Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vtv-therapeutics#company-drugs.

• What are the latest developments for vTv Therapeutics?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does vTv Therapeutics focus on?

  vTv Therapeutics focuses on Alzheimer's Disease, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1 based on our analysis of their pipeline programs and drug development activities.